Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Director | September 17, 2026 | September 21, 2026 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Chief Financial Officer | February 20, 2019 | February 22, 2019 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Financial Officer | June 04, 2021 | June 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2036-09-16 | Direct | 12,200 |
Reported balance
After 2026-09-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-17 · Grant · Acquired Not disclosed · Balance 12,200 F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.
Strongbridge Biopharma plc
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 33,366 |
Reported balance
After 2019-02-20 transaction · row 1
1 source rowRow 1 · 2019-02-20 · Grant · Acquired 20,000 · Balance 33,366 F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2029-02-20 | Direct | 108,500 |
Reported balance
After 2019-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-20 · Grant · Acquired 108,500 · Balance 108,500 F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.
Verrica Pharmaceuticals Inc.
Report date June 04, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,900 |
Reported balance
After 2021-06-04 transaction · row 1
1 source rowRow 1 · 2021-06-04 · Purchase · Acquired 5,000 · Balance 12,900 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 20:20 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | Not disclosed | $0.00 Strike: $2.13 | $12,200.00 |
DisclosureSEC source: 0001140361-26-037245 · form4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires 2036-09-16 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:01 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001140361-26-000966 · form4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:21 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001140361-25-018695 · form4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-09 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:06 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0000950170-23-071877 · ownership.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Class A Common Shares · 22,500 shares Expires 2033-12-19 F1 · derivative.exercise_date: Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant). Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 12:41 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 5,000 | $9.89 | $49,450.00 |
DisclosureSEC source: 0001209191-21-038480 · doc4.xml · nonDerivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $9.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:05 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0001209191-21-016997 · doc4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:38 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 7,900 | $6.24 | $49,296.00 |
DisclosureSEC source: 0001209191-20-046962 · doc4.xml · nonDerivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.19 to $6.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:46 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001209191-20-014683 · doc4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 20:49 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $14.65 | $0.00 |
DisclosureSEC source: 0001209191-19-053716 · doc4.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-10-18 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on October 18, 2020 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 08:50 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantEmployee Stock Option (right to buy) · Derivative | 108,500 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001179110-19-002285 · edgar.xml · derivative · entry 2 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,500 Underlying: Common Stock · 108,500 shares Expires 2029-02-20 F2 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 08:50 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002285 · edgar.xml · nonDerivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,366 F1 · shares: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 14:37 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | Tax withholdingOrdinary Shares | 8,696 | $6.60 | $57,393.60 |
DisclosureSEC source: 0001179110-18-003028 · edgar.xml · nonDerivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,366 F1 · shares: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 16:58 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantEmployee Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001179110-18-001636 · edgar.xml · derivative · entry 1 DAVIS A BRIAN · CIK 0001184432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2028-02-05 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning May 5, 2018, provided employee is employed by the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.